v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04813471 |
Full text link
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
matlikamal@gmail.com |
Registration date
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
2021-03-24 |
Recruitment status
Last imported at : March 14, 2023, midnight Source : ClinicalTrials.gov |
Unknown |
Study design
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Open label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
inclusion criteria: - participants must be 18 years of age or older - participants must have a pcr confirming covid 19 status - participants must be classified as critical as per the fda evidence of critical illness, which is defined as respiratory failure requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high- flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20 l/min with fraction of delivered oxygen ≥ 0.5), noninvasive positive pressure ventilation, ecmo, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation) - eligible for or already taking statin |
Exclusion criteria
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
- patients who are already on statins or nicorandil. - patients labeled as having mild, moderate or severe covid-19 infection as per the fda definitions. - patients with shock as defined by sbp<90 for more than 30 minutes not responding to iv fluids with evidence of end organ damage. - severe hepatic impairment (child-pugh class c) or active liver disease are absolute reasons not to be included especially those with unexplained persistent elevations of serum transaminases. - pregnancy or breastfeeding - hypersensitivity to any of the above-mentioned medications - on levodopa. - patients on pde5 inhibitors, riociguat - acute pulmonary edema - hypovolemia - leber's disease |
Number of arms
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Lebanese American University Medical Center |
Inclusion age min
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
99 |
Countries
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Lebanon |
Type of patients
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Critical disease at enrollment |
Severity scale
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
8: Critical disease at enrollment |
Total sample size
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
70 |
primary outcome
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Clinical Improvement |
Notes
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Phase 3 |
Arms
Last imported at : March 26, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 1520, "treatment_name": "Atorvastatin+folic acid+l-arginine+nicorandil+vitamin b", "treatment_type": "Metabolic agents+vitamins and dietary supplements+cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |